5 Key Takeaways

• 1

  Radiopharmaceuticals combine radioisotopes with biological molecules for targeted diagnostic and therapeutic applications.

• 2

  The global market for radiopharmaceuticals is projected to grow from $7.9 billion in 2023 to $21.8 billion by 2033.

• 3

  Lutetium-177 is the most widely used therapeutic isotope, effectively targeting cancer cells while minimizing damage to healthy tissue.

• 4

  Clinical trials show significant improvements in disease progression and survival rates for patients treated with radiopharmaceuticals.

• 5

  Access to radiopharmaceuticals is challenged by supply chain issues, workforce shortages, and inequities between high- and low-income countries.